Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to Eli Lilly’s (LLY) tirzepatide. Share price reaction ...

In the REDEFINE 2 trial, CagriSema led to 15.7% weight loss after 68 weeks, compared to 3.1% with placebo, with 89.7% achieving at least 5% Novo Nordisk plans to seek regulatory approval for ...

Novo Nordisk A/S Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial ...

The combination works by decreasing hunger and increasing the feeling of fullness. The REDEFINE 2 trial (ClinicalTrials.gov Identifier: NCT05394519) evaluated the efficacy and safety of CagriSema ...